Carle Jasmin (Image : AI / Gay Globe)

Another social media post deserves closer examination, particularly with regard to its accuracy and, above all, its implications.

In an article published on the ScienceAlert website, the headline reads: “A Dose of an Experimental Antibody Kept a Virus Closely Related to HIV in Remission in a Monkey for Four Years,” with the subtitle: “A Surprising Pathway Toward a Possible HIV Cure.”

Unfortunately, this kind of publication, which is irresponsible and borders on misinformation, risks giving false hope to people living with HIV. This is true even though the information is based, at its core, on certain scientific findings that nevertheless need to be put into perspective.

A single injection of an experimental antibody enabled a macaque infected with a virus related to HIV to remain without detectable virus in its blood for four years after antiretroviral treatment was discontinued. This discovery opens up an interesting avenue in the search for sustained HIV remission.

A study published on October 19, 2026, in the prestigious scientific journal Nature Microbiology provides new insight into strategies aimed at reducing or even eliminating the viral reservoirs responsible for HIV persistence in the body.

The researchers worked with newborn rhesus macaques infected with SIV, or simian immunodeficiency virus, which is closely related to HIV. The objective was to determine whether a very early immunological intervention could prevent the virus from establishing long-term reservoirs in the body’s cells.

The animals initially received standard antiretroviral treatment consisting of three drugs. Some also received a single injection of an experimental bispecific antibody targeting two cellular markers, CCR5 and CD3.

This approach is particularly interesting. CCR5 is a receptor used by many HIV and SIV strains to enter cells. The experimental antibody helps mobilize the immune system against cells expressing this receptor, thereby contributing to the elimination of some of the cells that could potentially harbor the virus.

After approximately 18 weeks of antiretroviral treatment, the medications were discontinued to determine whether the virus would reappear.

In the animals that received antiretroviral drugs alone, the virus quickly returned to the bloodstream, generally within seven days of stopping treatment. The situation was different in the macaques that received the experimental antibody. Several experienced a considerable delay in viral rebound, and some showed no detectable viral recurrence throughout the observation period.

The most remarkable result involved one animal that remained without detectable virus for four years after antiretroviral treatment was discontinued. The researchers also conducted extensive analyses to look for traces of viral genetic material in different tissues. In some animals that maintained remission, the tests failed to detect any virus capable of replication.

This observation is important because the main obstacle to an HIV cure remains the persistence of viral reservoirs. Even when treatment makes the viral load undetectable, certain cells retain viral genetic material that can restart the infection when medication is discontinued.

The approach being studied therefore seeks to act directly on these cells and reduce the possibility of the viral reservoir being re-established.

However, it is important to avoid drawing premature conclusions. The experiment was conducted in very young macaques that were treated very soon after infection. The results do not demonstrate that this method would work in the same way in adults who have been living with HIV for several years. Furthermore, eliminating CCR5-expressing cells could have immunological consequences that will need to be carefully assessed.

Nevertheless, the researchers believe this strategy deserves further investigation, particularly in cases of infection detected and treated very early. It could eventually be combined with other immunological approaches to achieve an even greater reduction in viral reservoirs.

For people living with HIV and the scientific community, this research represents an encouraging avenue of investigation. It is not an available cure, nor a new treatment intended for patients. Rather, it demonstrates that a single immunological intervention could, under certain experimental conditions, produce an exceptionally long-lasting effect.

Research into treatment-free remission continues to advance, with an objective that remains central: one day enabling people living with HIV to control the virus over the long term without having to take medication for the rest of their lives.

ADVERTISING

READ ALSO

1. HIV: Anti-PD-1 Immunotherapy, a Promising Path Toward Durable Remission
https://gayglobe.net/hiv-anti-pd-1-immunotherapy-durable-remission/

2. HIV: New Statistics Reveal a Reality That Few People Are Aware Of
https://gayglobe.net/en/rising-hiv-cases/

3. The Last Witnesses: What Survivors of the AIDS Epidemic Want to Pass On to Young LGBTQ+ People Before They Are Gone
https://gayglobe.net/en/hiv-lgbt-rights-history/

4. HIV: What Undetectable = Untransmittable Really Means and the Risks of a Viral Blip
https://gayglobe.net/hiv-what-undetectable-untransmittable-really-means-and-the-risks-of-a-viral-blip/

5. HIV: The Myth of Patient Zero
https://gayglobe.net/hiv-the-myth-of-patient-zero/

6. HIV and Misinformation: The History of Miracle Cures and Scams
https://gayglobe.net/hiv-misinformation-online/